Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide [Phase 1, Phase 2]
Phase 1/2 trial evaluating pomalidomide with cyclophosphamide and prednisone (PCP) in patients with relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial of Delanzomib in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma has completed wi…
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma [Phase 2]
Phase 2 diagnostic study evaluating CD38-targeted ImmunoPET for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone [Phase 2]
Phase 2 study evaluating the clinical benefit of lenalidomide in combination with dexamethasone for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial update evaluating chemotherapy and peripheral stem cell transplantation in patients with multiple myeloma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) [Phase 1, Phase 2]
Phase 1/2 trial update for P-BCMA-101 Tscm CAR-T cells in multiple myeloma; trial status terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma [Phase 2]
Phase 2 trial evaluating VRD as induction followed by VR maintenance in newly diagnosed high-risk multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation [Phase 2]
Phase 2 clinical trial evaluating a biological therapy for multiple myeloma that recurred after bone marrow transplantation has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating ATG-010 in relapsed/refractory multiple myeloma has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating combination chemotherapy with or without PSC 833 in relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-12Clinical Trial Update: LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for LCAR-B38M cells in relapsed/refractory multiple myeloma (Phase 1/Phase 2) is provided, with unspecified status.
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating melflufen in combination with daratumumab in relapsed or relapsed-refractory multiple myeloma was terminated; res…
-
CLINICAL_TRIALS trial_result · 2023-06-06Clinical Trial Update: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial update on pomalidomide, bortezomib, and low-dose dexamethasone in relapsed or refractory multiple myeloma; results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: BiRd vs. Rd as Initial Therapy in Multiple Myeloma [Phase 3]
Phase 3 trial comparing BiRd versus Rd as initial therapy in multiple myeloma was terminated; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-05-26Clinical Trial Update: Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant [Phase 2]
Phase 2 trial evaluating lenalidomide as maintenance therapy after tandem autologous and allogeneic transplant in newly diagnosed multiple m…
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on high-dose BeEAM chemotherapy with autologous transplant in multiple myeloma; study completed with results p…
-
CLINICAL_TRIALS trial_result · 2023-05-15Clinical Trial Update: T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma [Phase 1]
Phase 1 trial evaluating T cells engineered to express a fully-human anti-BCMA CAR for treating multiple myeloma; results were posted in 202…
-
CLINICAL_TRIALS trial_result · 2023-05-15Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating mitoxantrone hydrochloride liposome injection for relapsed/refractory multiple myeloma is underway with unknown s…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM [Phase 3]
Phase 3 trial comparing elotuzumab with carfilzomib, lenalidomide, and dexamethasone (E-KRd) versus KRd in newly diagnosed multiple myeloma;…
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Daratumumab in Combination With ATRA [Phase 1, Phase 2]
Phase 1/2 trial evaluating daratumumab in combination with ATRA in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Reduced Intensity Conditioning Transplant Using Haploidentical Donors [Phase 2]
Phase 2 clinical trial investigating reduced intensity conditioning transplant using haploidentical donors for various hematologic malignanc…
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance [Phase 3]
Phase 3 trial comparing RAD vs VRD induction in newly diagnosed multiple myeloma with response-adapted consolidation and lenalidomide mainte…
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM [Phase 1, Phase 2]
A clinical trial update reports on the safety and efficacy of anti-GPRC5D CAR-T cell therapy for relapsed or refractory multiple myeloma acr…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
An update on safety and efficacy of a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma from Phase 1/Phase 2 trials.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies [Phase 1]
Phase 1 trial updating safety, tolerability, pharmacokinetics, and efficacy of AMG 397 in relapsed or refractory hematological malignancies;…